Biogen (BIIB) Could be Valued at $42B Cash in Samsung Deal, Here Are Key Questions According to Truist Securities
Tweet Send to a Friend
Truist analyst Robyn Karnauskas reiterates a "Buy" rating and $502 price target on shares of Biogen (NASDAQ: BIIB), following rumors ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
